MedPath

GlycoVaxyn AG

GlycoVaxyn AG logo
🇨🇭Switzerland
Ownership
Private, Subsidiary
Established
2004-01-01
Employees
11
Market Cap
-
Website
http://www.glycovaxyn.com

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Vaccine Against Escherichia Coli Infection

Phase 1
Completed
Conditions
E.Coli Infections
First Posted Date
2014-11-13
Last Posted Date
2016-02-11
Lead Sponsor
GlycoVaxyn AG
Target Recruit Count
194
Registration Number
NCT02289794
Locations
🇨🇭

Hôpitaux Universitaires de Genève, Geneve, GE, Switzerland

Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella

Phase 1
Completed
Conditions
Shigellosis
First Posted Date
2010-02-17
Last Posted Date
2010-10-13
Lead Sponsor
GlycoVaxyn AG
Target Recruit Count
40
Registration Number
NCT01069471
Locations
🇨🇭

Institute of Social and Preventive Medicine, Zurich, Switzerland

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.